Nyxoah Reports Strong Q4 & FY2025 Revenue Growth, Positive Q1 2026 Guidance, and Successful U.S. Launch
Summary
Nyxoah announced preliminary unaudited financial results for Q4 and full year 2025, showing significant revenue growth driven by a strong U.S. commercialization launch, and provided positive revenue guidance for Q1 2026.
Key Events
-
Strong Revenue Growth
Preliminary Q4 2025 net revenue increased by approximately 348% year-over-year to €5.7 million, with full year 2025 net revenue growing 122% to €10.0 million.
-
Successful U.S. Commercialization
The company reported a strong U.S. launch with approximately €3.5 million in U.S. net revenue for Q4 2025, 145 surgeons trained, and 57 accounts activated.
-
Positive Q1 2026 Guidance
Nyxoah expects U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over Q4 2025.
-
Solid Cash Position
As of December 31, 2025, cash, cash equivalents, and financial assets were approximately €47.9 million.
Analysis
The preliminary financial results indicate robust performance, particularly with the substantial year-over-year revenue growth in both the fourth quarter and full year 2025. The successful U.S. commercialization, marked by surgeon training and account activation, highlights effective market penetration for its Genio system post-FDA approval. The positive revenue guidance for the first quarter of 2026 suggests continued momentum. Additionally, the disclosure of BNP Paribas Asset Management crossing the 3% ownership threshold, while attributed to an internal merger, signifies increased institutional presence. These factors collectively paint a positive picture for Nyxoah's operational trajectory and investor confidence.
At the time of this filing, NYXH was trading at $5.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $220.3M. The 52-week trading range was $4.35 to $11.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.